Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee et al.|The Lancet|2024Cited by 233
Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell CarcinomaWei Guo, Jié He, Fengwei Tan et al.|Frontiers in Immunology|2021Cited by 84
Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLCFan Zhang, Jie He, Wei Guo et al.|Journal of Thoracic Oncology|2022Cited by 74
Associations of PGK1 promoter hypomethylation and PGK1‐mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan‐cancer analysisFei Shao, Jie He, Xueying Yang et al.|Cancer Communications|2019Cited by 50
Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung CarcinomaXueying Yang, Jie He, Fei Shao et al.|Frontiers in Oncology|2019Cited by 32